retatrutide type 2 diabetes phase 2 trial hba1c Effects of retatrutide, dulaglutide, and placebo on gastric emptying in Triple hormone receptor agonist retatrutide

Aggressive management strategies become essential rather than optional

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and still being evaluated in Phase 2 and Phase 3 clinical trials

Similar combinations of active biological agents might minimise the unwanted cardiovascular effects of traditional small-molecule-based drugs or target anti-inflammatory pharmacology to only certain select tissues

Imbriani P, Martella G, Bonsi P, Pisani A (2022) Oxidative stress and synaptic dysfunction in rodent models of Parkinsons disease

According to the American Diabetes Association (ADA) Standards of Care, GLP-1 receptor agonists with proven cardiovascular benefit are recommended for many patients with type 2 diabetes who have established cardiovascular disease, with individualized therapy based on patient factors

Our team at The Peer Group will continue to monitor and evaluate each patients progress all while providing ongoing support and monitoring throughout their weight loss journey